CSL earnings preview: analysts remain bullish before H1 results
We examine some of the key things investors need to know before CSL releases its FY20, first-half results.
CSL’s recent share price run up is most intriguing maybe because of the company’s monolithic size.
Indeed, over the last twelve months the stock has risen an enviable 69.2% and now, at a market capitalisation of ~$145 billion, represents the second largest publicly-listed company in Australia.
The Commonwealth Bank of Australia (ASX: CBA) is of course the largest, beating out CSL is terms of market value by just a couple of billion – with the bank currently valued at ~$147 billion.
All up, CSL now counts itself as the third largest biotech in the world.
Even when considering this share price run up, analysts still continue to favour CSL – on average – with 57.1% of analysts covering the stock currently rating it a buy, according to Bloomberg Data. In contrast, five analysts rate the stock a hold and only one analyst rates the stock a sell – as we head into the company’s first-half FY20 results.
In saying that, the average 12-month analyst price target may suggest that CLS has run a shade ahead of itself – at current price levels, at least. Here, and on average, analysts peg CSL’s fair value at $294.34 per share, according to Bloomberg Data.
On that estimate, investors would be looking at potential downside of ~7.5% at today’s prices.
The dates investors need to know
CSL is set to release its first-half, FY20 results on 12 February.
Likely to the interest of income-focused investors, the company’s ex-dividend date is currently set at 11 March, with this interim dividend set to be paid on 9 April.
The biotech giant has a current annual dividend yield of 0.85%, according to the ASX.
CSL share price and the UBS thesis
UBS has been one of the most persistently bullish brokers on CSL’s prospects over the last 12-months. Even so, the investment bank notes that the biotech giant is currently trading at a significant 103% premium to the broader market (ASX 200) – on the basis of a 12-month forward consensus EPS, as we head into the company’s H1 results.
Moreover, the investment bank today noted that they were currently reviewing their price target and rating on CSL. It will be interesting to see what comes of this review and when it occurs.
Even still, UBS expects robust revenue growth in CSL's Immunoglobulin (IG) segment, remaining a key driver for the stock – with UBS forecasting +16% volume growth.
UBS is currently forecasting CSL to report first-half FY20 revenues of US$4,870.0 million, against earnings (EBITDA) of US$1,906.6 million.
This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.